TSHA Taysha Gene Therapies, Inc.
Legal ·
Stockholders sued in Delaware Chancery over the August 2023 private placement. A special litigation committee moved on March 3, 2026 to end the case, and the lead plaintiff does not oppose.
Taysha filed an automatic shelf on November 4, 2025, with a sales agreement of up to $200,000,000 of common stock. As of November 3, 2025, it had sold $12,000,000 under the earlier agreement, while its third-quarter net loss was $32.7 million.
Common stock authorized rises from 400,000,000 shares. The company filed the amendment in Delaware on June 2, 2025.
Taysha Gene Therapies agreed to sell 46,868,687 shares and pre-funded warrants for 25,858,586 more at $2.75 a share, with net proceeds estimated at $187.4 million. The company says that money and its existing cash will last into 2028, and the filing names no lawsuit or defendant.
Taysha Gene Therapies filed a $300,000,000 shelf registration on December 13, 2024, with a $100,000,000 at-the-market sales agreement inside it. The company had sold $12,000,000 under its earlier agreement, and the stock's last reported price was $2.25.
Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder for which the company says no approved disease-modifying therapies address the genetic root cause. The company is evaluating TSHA-102 for the treatment of females with Rett syndrome in its REVEAL and ASPIRE clinical trials. The REVEAL trial is a Phase 1/2 study in adolescents and adults. Taysha says it uses a clinically and commercially proven AAV9 capsid and a manufacturing process developed by its management team, which has experience in gene therapy development and commercialization. The company's stated aim is to translate treatments rapidly from bench to bedside and to address severe unmet medical needs for patients and their caregivers.
| Product or program | What it is | Stage |
|---|---|---|
| TSHA-102 | AAV gene therapy for Rett syndrome in females | Phase 1/2 (REVEAL) |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $9.8 million | $8.3 million |
| Research and development | $86.4 million | $66.0 million |
| Net income (loss) | -$109.0 million | -$89.3 million |
| Cash from operations | -$93.1 million | -$81.2 million |
| Cash and equivalents | $319.8 million | $139.0 million |
Our latest story on this, dated Aug 11, 2026: "Taysha derivative suit over 2023 private placement faces termination motion". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 11, 2026: "Taysha derivative suit over 2023 private placement faces termination motion". The story links the filing or release it is based on. Read the story.
Taysha Gene Therapies, Inc. trades under the ticker TSHA on NASDAQ.
Taysha Gene Therapies, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Taysha Gene Therapies, Inc. is 1806310. Its filings are on SEC EDGAR.
325,833,545 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Taysha Gene Therapies, Inc. under United States.
Our directory classifies Taysha Gene Therapies, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Taysha Gene Therapies, Inc. is US8776191061.
aibio.space lists Taysha Gene Therapies, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder for which the company says no approved disease-modifying therapies address the genetic root cause.
TSHA-102: AAV gene therapy for Rett syndrome in females Stage: Phase 1/2 (REVEAL).
$9.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Taysha Gene Therapies, Inc. reported a net loss of $109.0 million for the fiscal year ended Dec 31, 2025, and used $93.1 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 8-K (Items 1.01,2.02,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio